Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
what a turd !!
grabbed few 1.90
Starter here - way too cheap!!!!
Looking for a bounce off 50sma maybe here!!!
Last contrarian pump was not very good, though...Lol...
3.70 Strong Close.. Help up pretty nice despite low volume and market sentiment with fed meeting this week. Meeting not till Wednesday i believe so we may have another day tomorrow for it to at least climb to 4's again
KBIO I BOUGHT RIGHT BEFORE CLOSE ON SEPT 3RD AT $2.99 sold the next morning $4.60. I rebought support area $3.43 (almost sold it due to dip . my 5% loss rule would have been inforced) and sold the bounce at $4.50. Looking to re-enter again. I will be posting my trades on twitter from now on..
KBIO LOOKING SEXY
I think I'm ok with close? (yes I'm questioning myself) Not sure what to make of today's action.. never like pullbacks and would have liked It if it stayed above 4.00 but overall higher lows and higher highs a good sign. I've been reading it has like a 3mil float, which would explain the pops but how many more can we get and are we expecting higher than 5's without news with that small float?
Got me some high 3s today. I think we will get another little gap up monday. May not be as big as today but 4.20-4.40 is good with me
Second day in same week with huge pop and similar pull back.. is this really expected to run and to where and why or is it being pumped for quick profits and set to crash? See cup and candle may be forming but not sure what to make of this
Filling that gap up there would be great but:
More like a Friday technical pop till now....
Light Volume lately, so many are holding for more...
$12+ we go by nxt week myop $$$$$$$$$
volume is goinnnnnn
hey, we cudda been in ttph. hehehe
they are looking for a partner.when this will take place,game on.read my previous post
http://seekingalpha.com/article/2970526-gerons-gern-ceo-john-scarlett-on-q4-2014-results-earnings-call-transcript?page=3
" we are conducting a business development effort to explore, identify and perform diligence reviews of potentially promising oncology product candidate programs and/or companies that if acquired or partnered by Geron may allow the company to diversify its development portfolio".
KBIO?
"KaloBios is open to partnering its programs with partners who share out commitment to advancing our Humaneered® antibodies. These partners should share our commitment to advancing our Humaneered® monoclonal antibodies so that patients may benefit from these medicines. Given the stage of these programs, we seek partners that recognize innovation, strive for excellence, and have strong expertise in mid-to-late stage development, regulatory approval and commercialization of monoclonal antibodiesin the indications being pursued."
Not trying to be difficult here, just trying to make sure I understand everything.
According to the Aug 10, 10Q the operating loss for the last 6 months was $15,662,000. If that holds true for the rest of 2015 then a huge portion of their cash and equivalents will be used by January. This assumes no increase in trial costs, R&D or general administrative expenses. Since it is always best to raise money before needed, it would seem logical for them to do a capital raise in the next 3-6 months or at least file an S-3.
Are there any grants or partnership considerations on the horizon that could mitigate the amount needed?
Since there agreement with Sanofi was terminated and work on the KB001-A suspended;
" Based on results of the Phase 2 data released in early 2015, we have discontinued development of KB001-A in all indications." ; I assume there will be no further funding/licensing or agreements with Sanofi.
Since trial phases run into the tens of millions and succeeding trials usually increase in cost I am also concluding the need for further capital infusion.
Take into consideration my dd is not complete. Please correct, add to and/or point me to other facts to round out the picture.
Thanks. IMO it looks like an early stage bio with a lot of promise and upside.
KBIO
KBIO is just me buying here?.Cash/share value almost twice market cap.
"We have made excellent progress in 2015 in strengthening our oncology focus at KaloBios," said Herb Cross, KaloBios' Chief Financial Officer and Interim Chief Executive Officer. "We continue to work to expand our portfolio of oncology programs in clinical development, most notably with the addition of a third oncology indication as a result of the July FDA clearance of our IND for KB003 in CMML. We continue to enroll patients in the KB004 Phase 2 program in MDS and MF, as well as evaluating additional potential oncology indications for KB004 including solid tumors where EphA3 is expressed. With several oncology indications either in development or moving into the clinic, and other potential indications under evaluation, we continue to be excited about the potential of our assets."
"Based on current enrollment rates, and with several additional clinical sites expected to commence enrollment in the coming months, the company expects enrollment to continue to accelerate. The drug continues to be well tolerated with the most commonly reported side effects being infusion reactions".
mm just dropped to stops,,ready to pop big $$$ myop
KBIO per this updates should come this year.link back
Screw your CHART BULLSHIT, stock moving on pure speculation, ready for a twenty dollar price imo
KaloBios is running phase 1 for Brain Cancer Patients
"A world-first human trial set to begin in Brisbane and Melbourne has the potential to be one of the biggest breakthroughs in the treatment of brain cancer, researchers say."
http://www.abc.net.au/news/2014-11-25/human-trials-begin-on-brain-cancer-treatment/5917512
(Can someone help post this info on Yahoo message board)
Nice DD king...I agree that huge volume is not all pennystockers..
marked you 868 great pick
83% ownership !! http://finance.yahoo.com/q/mh?s=KBIO+Major+Holders
% of Shares Held by All Insider and 5% Owners: 19%+ % of Shares Held by Institutional & Mutual Fund Owners: 64%
KBIO "The stock has a consensus analyst price target of $5.00 and a 52-week trading range of $1.71 to $17.20".
Read more: Top 4 Movers in Friday’s Session - 24/7 Wall St. http://247wallst.com/investing/2015/09/04/top-4-movers-in-fridays-session/#ixzz3koGMwfzK
Follow us: @247wallst on Twitter | 247wallst on Facebook
* * $KBIO Video Chart 09-04-15 * *
Link to Video - click here to watch the technical chart video
3 brokers confirmed so far NO SHORTS AVAILABLE
KBIO. Fingers Crossed for a Deal with Geron. have a great weekend all.
thanks for your update,it seems no one can short KBIO
schawb brokerage just told me,,no shares availble to short,hmmmmm
may move big a/h tonite,,up i hope lol $$$
KBIO:Insane Volume.Somebody-knows-something like they say on the OTC-Boards.Lol
also could open $6 +, don't forget AQXP ran to $400m cap,KBIO's cap less than $15m now.
Cash alone is $23m as reported last week.
Wait for a bigger pull back. It Friday and peeps are selling. Plus Monday a Holiday and the Market is close.
aqxp on fire again also,,wow myop
gonna hold this thru weekend.the volume is huge, we might hear something next week imo
With a low float and o/s, there is a possibility it could do a AQXP next Tuesday, who knows.
With no shorts available skies the limit if good updates hits imo.never saw it before.this a good reason to keep holding this. on good updates this might make AQXP move.Cap is still very low and they have $23m in cash.very solid balance sheet
Knew I should have sold around 11AM. Looks like it's time to wait and see.
Followers
|
328
|
Posters
|
|
Posts (Today)
|
9
|
Posts (Total)
|
42654
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators DTGoody cowtown jay TheGreatSwami |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |